Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Partech in connection with its investment in Billogram
Mandate

Vinge has advised Partech in connection with its investment in Billogram

September 14, 2021 M&A

Vinge has advised global tech investment firm Partech with its 35 MEUR investment into Billogram.

The new capital will go directly into Billogram's expansion into six new markets and doubling its workforce. Partech is known for investing in global European-born software leaders Ecovadis, M-Files or Sendinblue, unicorns such as Jellysmack, Rohlik, Sorare, Toss and Swedish digital native fashion brand NA-KD. Billogram provides a customer relationship-strengthening software platform that secures payments on time, increases customer satisfaction, and prevents churn.

Vinge’s team primarily consisted of Johan Larsson, Ulrich Ziche, Maria Dahlin Kolvik, Rickard Vernet, Selma Beganovic, Daniel Daun and Johanne Örnfeldt Svensson.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026